Brain neuropeptides in progressive supranuclear palsy

No significant alterations in the levels of Met-enkephalin-, Leu-enkephalin-, cholecystokinin- and substance P-like immunoreactive materials were found in 10 areas of postmortem brains from patients with progressive supranuclear palsy (PSP) when compared to controls. These results are at difference...

Full description

Saved in:
Bibliographic Details
Published inBrain research Vol. 411; no. 1; p. 178
Main Authors Taquet, H, Javoy-Agid, F, Mauborgne, A, Benoliel, J J, Agid, Y, Legrand, J C, Hamon, M, Cesselin, F
Format Journal Article
LanguageEnglish
Published Netherlands 12.05.1987
Subjects
Aged
Brain - metabolism
Cholecystokinin - metabolism
Corpus Striatum - metabolism
Corpus Striatum - pathology
Dopamine - metabolism
Enkephalin, Leucine - metabolism
Enkephalin, Methionine - metabolism
Humans
Neuropeptides - metabolism
Substance P - metabolism
Substantia Nigra - metabolism
Substantia Nigra - pathology
Supranuclear Palsy, Progressive - metabolism
Online AccessGet more information

Cover

More Information
Summary:No significant alterations in the levels of Met-enkephalin-, Leu-enkephalin-, cholecystokinin- and substance P-like immunoreactive materials were found in 10 areas of postmortem brains from patients with progressive supranuclear palsy (PSP) when compared to controls. These results are at difference with the marked decrease in the levels of enkephalin-, cholecystokinin- and substance P-like immunoreactive materials previously reported in the basal ganglia of parkinsonian patients. Since PSP and Parkinson's disease are both characterized by a severe dopamine nigrostriatal deficit, these results suggest that the decreased brain peptide concentrations found in Parkinson's disease do not simply result from a dopaminergic neuronal loss.
ISSN:0006-8993
DOI:10.1016/0006-8993(87)90697-4